J Natl Cancer Inst

• 

  Publication Venue For

  • Predictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims..  113:1581-1589. 2021
  • Response to Dekker, Stege, and Versteeg..  113:1436-1437. 2021
  • Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors. 2021
  • Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living With Cancer Study..  113:1053-1064. 2021
  • Early Medicaid Expansion and Cancer Mortality. 2021
  • Hodgkin Lymphoma Survivors: We Need to Do Better..  113:654-655. 2021
  • Racial Differences in Population Attributable Risk for Epithelial Ovarian Cancer in the OCWAA Consortium..  113:710-718. 2021
  • A Comparison of Late Mortality Among Survivors of Childhood Cancer in the United States and United Kingdom..  113:562-571. 2021
  • Sex-Specific Associations Between Chemotherapy, Chronic Conditions, and Neurocognitive Impairment in Acute Lymphoblastic Leukemia Survivors: A Report From the Childhood Cancer Survivor Study..  113:588-596. 2021
  • Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. 2021
  • Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia..  113:408-417. 2021
  • Opioid Use Disorder and Overdose in Older Adults With Breast, Colorectal, or Prostate Cancer..  113:425-433. 2021
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy..  113:443-452. 2021
  • Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies..  113:301-308. 2021
  • Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. 2021
  • Personalized Cancer Follow-Up Care Pathways: A Delphi Consensus of Research Priorities..  112:1183-1189. 2020
  • Response to Strassels and Durham..  112:1280. 2020
  • Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events..  112:1143-1152. 2020
  • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design..  112:1021-1029. 2020
  • The Affordable Care Act's Medicaid Expansion and Impact Along the Cancer-Care Continuum: A Systematic Review..  112:779-791. 2020
  • Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women..  112:728-736. 2020
  • Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer..  112:765-768. 2020
  • Radiation Dose and Volume to the Pancreas and Subsequent Risk of Diabetes Mellitus: A Report from the Childhood Cancer Survivor Study..  112:525-532. 2020
  • Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors..  112:256-265. 2020
  • Response to Habel and Buist..  112:216-217. 2020
  • Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas..  112:95-106. 2020
  • Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors..  111:1245-1254. 2019
  • Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors..  111:1161-1169. 2019
  • Cancer Outcomes in DCIS Patients Without Locoregional Treatment..  111:952-960. 2019
  • Childhood Leukemia, Late Effects, and a Person-centric Model of Follow-up..  111:880-881. 2019
  • Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance)..  111:170-179. 2019
  • Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage..  111:60-68. 2019
  • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer..  110:1360-1369. 2018
  • Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients..  110:1084-1093. 2018
  • Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms..  110:1067-1074. 2018
  • Defining Value of Cancer Therapeutics-A Health System Perspective..  110:699-703. 2018
  • Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project..  110:638-648. 2018
  • Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance..  110:420-425. 2018
  • The Future of Radiobiology..  110:329-340. 2018
  • Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study..  110. 2018
  • Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer..  109. 2017
  • Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research..  109. 2017
  • Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies..  109. 2017
  • Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies..  109. 2017
  • Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer..  109. 2017
  • Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer..  109. 2017
  • What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?.  109. 2017
  • Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans..  108. 2016
  • Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors..  108. 2016
  • Financial Toxicity of Cancer Care: It's Time to Intervene..  108. 2016
  • Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis..  108. 2016
  • The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative..  108. 2016
  • Role of Increased n-acetylaspartate Levels in Cancer..  108:djv426. 2016
  • The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)..  107:djv261. 2015
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ..  107:djv263. 2015
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer..  107. 2015
  • Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)..  107. 2015
  • Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases..  107. 2015
  • On the quantitative assessment of predictive biomarkers..  107. 2015
  • Supplemental security income and social security disability insurance coverage among long-term childhood cancer survivors..  107:djv057. 2015
  • Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise..  107. 2015
  • Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood..  107. 2015
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer..  107. 2015
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer..  107:345. 2015
  • Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass..  107:322. 2015
  • Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802)..  107:336. 2015
  • Germline mutations in shelterin complex genes are associated with familial glioma..  107:384. 2015
  • Opportunities-and hard work-ahead..  107:398. 2015
  • RE: net risk reclassification P Values: valid or misleading?.  107:355. 2015
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas..  106. 2014
  • Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)..  106. 2014
  • 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance)..  106. 2014
  • ABCA transporter gene expression and poor outcome in epithelial ovarian cancer..  106. 2014
  • Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials..  106. 2014
  • Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials..  106. 2014
  • Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials..  106. 2014
  • Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials..  106. 2014
  • Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer..  106. 2014
  • Impact of patient navigation on timely cancer care: the Patient Navigation Research Program..  106:dju115. 2014
  • Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma..  106. 2014
  • Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis..  106. 2014
  • Multiple myeloma in the very old: an IASIA conference report..  106. 2014
  • Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony?.  106:dju042. 2014
  • Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium..  106:djt431. 2014
  • Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma..  106. 2014
  • Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis..  106. 2014
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial..  105:1789-1798. 2013
  • Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy..  105:1729-1737. 2013
  • Recommendations for high-priority research on cancer-related fatigue in children and adults..  105:1432-1440. 2013
  • Inhibiting the inhibitor: targeting vascular endothelial protein tyrosine phosphatase to promote tumor vascular maturation..  105:1163-1165. 2013
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects..  105:929-936. 2013
  • Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations..  105:733-742. 2013
  • Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy..  105:499-503. 2013
  • Validation of a breast cancer risk prediction model developed for Black women..  105:361-367. 2013
  • Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803..  104:1702-1711. 2012
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial..  104:1647-1659. 2012
  • Biological, clinical, and psychosocial correlates at the interface of cancer and aging research..  104:581-589. 2012
  • Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival..  103:1851-1858. 2011
  • Molecular characterization of the tumor-suppressive function of nischarin in breast cancer..  103:1513-1528. 2011
  • Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803..  103:1540-1551. 2011
  • Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk..  103:1342-1346. 2011
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1..  103:1190-1204. 2011
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy..  103:910-913. 2011
  • Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation..  102:1698-1705. 2010
  • Evidence that Gsta4 modifies susceptibility to skin tumor development in mice and humans..  102:1663-1675. 2010
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer..  102:1496-1512. 2010
  • Functional assessment and the cancer survivor: something old, something new..  102:1450-1451. 2010
  • Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study..  102:1272-1283. 2010
  • Testicular cancer survivorship: research strategies and recommendations..  102:1114-1130. 2010
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer..  102:942-949. 2010
  • Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism..  102:932-941. 2010
  • Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women..  102:325-339. 2010
  • Impact of cancer on health-related quality of life of older Americans..  101:860-868. 2009
  • Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding..  101:543-545. 2009
  • Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials..  101:256-266. 2009
  • The influence of statin medications on prostate-specific antigen levels..  100:1511-1518. 2008
  • Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens..  100:681-682. 2008
  • Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer..  100:158-159. 2008
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab..  99:1232-1239. 2007
  • Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium..  99:777-789. 2007
  • Response rate as an endpoint in clinical trials..  99:98-99. 2007
  • Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects..  99:53-63. 2007
  • Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)..  98:1335-1338. 2006
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model..  98:1238-1247. 2006
  • Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs..  98:1118-1128. 2006
  • Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation..  98:855-868. 2006
  • Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project..  98:724-725. 2006
  • Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers..  98:335-344. 2006
  • Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)..  98:92-100. 2006
  • In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis..  97:1822-1831. 2005
  • Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants..  97:1080-1083. 2005
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab..  97:981-989. 2005
  • Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..  97:94-102. 2005
  • Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial..  96:1083-1094. 2004
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure..  96:509-515. 2004
  • Selection bias, phase II trials, and the FDA accelerated approval process..  95:1351-1352. 2003
  • Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy..  95:1376-1383. 2003
  • RESPONSE: re: initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models.  92:1445-1446. 2000
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers..  108. 2016